UCLB, Kurma Biofund form partnership

UCLB is delighted to announce a partnership with Kurma Biofund, a recently formed venture capital fund based in Paris and dedicated to innovations in life sciences and healthcare. Kurma recently announced the closing of a first round of financing totalling -50 million.

An objective of the Fund is to extend selectively its relationships with leading institutions in other parts of Europe. Kurma has therefore established a close working relationship with UCLB to support the commercialisation of the intellectual property assets of UCL (University College London) at its Institute of Child Health.

"The partnership with UCL Business has an initial focus in child health, with the possibility of extending to other areas in the future. We selected child health because of the strength of UCL's Institute of Child Health, which is associated and works closely with Great Ormond Street Hospital, one of the world's leading centres for treating childhood illnesses. We have a dual goal: to help UCL Business to commercialise the intellectual assets of UCL and to realise breakthroughs in the treatment of diseases of children", said Louis Nisbet, the UK Venture Partner for Kurma."

"We are delighted to be working with the Kurma team. UCL's Institute of Child Health has some very exciting research and this partnership will ensure that together we will identify projects with the most promising potential to deliver solutions to treat childhood diseases", said Cengiz Tarhan, Managing Director of UCL Business."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare